Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation - 10/08/11
, William W. Busse, MD b, Sally E. Wenzel, MD c, Vasily Belozeroff, PhD d, Haoling H. Weng, MD, MHS d, JingYuan Feng, MS d, Yun Chon, PhD d, Chiun-Fang Chiou, PhD d, Denise Globe, PhD d, Shao-Lee Lin, MD, PhD d
Reprint requests: Eli O. Meltzer, MD, Allergy and Asthma Medical Group and Research Center, 9610 Granite Ridge Drive, Suite B, San Diego, CA 92123.Abstract |
Background |
Direct correlation of assessments of a validated composite measure such as the Asthma Control Questionnaire (ACQ) and risk of exacerbation has not been previously demonstrated in a randomized controlled trial.
Objective |
To evaluate the ability of the ACQ score over time to predict risk of a future asthma exacerbation.
Methods |
This analysis included data from a 12-week placebo-controlled trial (N = 292) of AMG 317, an IL-4 receptor ⍺ antagonist, in patients with moderate to severe atopic asthma. At baseline, patients had an ACQ score ≥1.5. Exacerbations were defined as requirement for systemic corticosteroids. A Cox proportional hazards model was used, with ACQ score as the time-dependent covariate. The analysis was repeated for individual components of the ACQ.
Results |
Each 1-point increase in ACQ was associated with a 50% increased risk of exacerbation (hazard ratio, 1.50; 95% CI, 1.03-2.20) for the following 2-week period. Evaluation of individual ACQ components also demonstrated a similar trend, though each to a lesser degree than the full composite ACQ.
Conclusion |
Although based on a retrospective analysis, with small number of exacerbations, these findings support the utility of the composite ACQ score measurement to predict risk of future exacerbation in clinical trials and clinical practice. The composite ACQ score measurement was found to be a better predictor of future risk than individual ACQ components.
Le texte complet de cet article est disponible en PDF.Key words : Asthma exacerbation, ACQ score, asthma control, prediction, IL-4 receptor ⍺, antagonist
Abbreviations used : ACQ, HR, MID, PEFR
Plan
| Supported by Amgen Inc. |
|
| Trial registration: This study is registered with ClinicalTrials.gov with the identifier NCT 00436670. |
|
| Disclosure of potential conflict of interest: E. O. Meltzer has received research support from UCB, Alcon, Alexza, Amgen, Antigen Labs, Apotex, Astellas, AstraZeneca, Boehringer Ingelheim, Capnia, Critical Therapeutics, GlaxoSmithKline, MAP, MEDA, Merck, Novartis, Proctor & Gamble, Schering-Plough, and Teva; has served as a consultant or on an advisory board for Schering Plough, Alcon, Alexza Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Capnia, Dainippon Sumitomo Pharma, Dey, ISTA, Johnson & Johnson, Kalypsys, MAP, Meda, Merck, National Jewish Health, Rady Children’s Hospital San Diego, Sandoz, Sepracor, SRxA, Teva, VentiRx, Wockhardt, and Wyeth; is a speaker for GlaxoSmithKline, MEDA, Merck, Sanofi-Aventis, Schering-Plough, Sepracor, and SRxA; has served as an expert in legal matters on the topics of desloratadine, fexofenadine, montelukast, and levocetirizine; and is a fellow for the AAAAI and the American College of Allergy, Asthma and Immunology. W. W. Busse is on the advisory board for Altair, GlaxoSmithKline, Merck, Wyeth, Pfizer Centocor, Amgen, and Johnson & Johnson; is a speaker for Merck; is a consultant for Novartis, Astra Zeneca, TEVA, Boehringer Ingelhim, and GlaxoSmith-Kline; and has received research support from NIH-NIAID, NIH-NHLBI, Novartis, AstraZeneca, GlazoSmithKline, MedImmune, and Ception. S. E. Wenzel is a consultant for GlaxoSmithKline, Merck, Amgen, and Pearl Therapeutics; is on the advisory board for Amira, Altair, and Epigenesis; and has received research support from GlaxoSmithKline, Amgen, and MedImmune. V. Belozeroff, H. H. Weng, D. Globe, and S.-L. Lin are employed by Amgen. Y. Chon holds stock in Amgen. The rest of the authors have declared that they have no conflict of interest. |
Vol 127 - N° 1
P. 167-172 - janvier 2011 Retour au numéro
Article précédent
- Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial
- Li Wang, Christopher S. Hollenbeak, David T. Mauger, Robert S. Zeiger, Ian M. Paul, Christine A. Sorkness, Robert F. Lemanske, Fernando D. Martinez, Robert C. Strunk, Stanley J. Szefler, Lynn M. Taussig, Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute
- Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis
- Sriram Vaidyanathan, Peter Williamson, Karine Clearie, Ashley Morrison, Brian Lipworth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?